Revance Therapeutics IncNASDAQ:RVNC
- LAST PRICE3.6200
- TODAY'S CHANGE (%)-0.1600 (-4.2328%)
- Bid / Lots3.6200/ 27
- Ask / Lots3.7200/ 6
- Open / Previous Close3.6700 / 3.7800
- Day Range
- 52 Week Range
- Volume1,896,957
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RVNC |
|---|---|---|
| 09:32 ET | 24292 | 3.75 |
| 09:33 ET | 85174 | 3.75 |
| 09:35 ET | 19058 | 3.75 |
| 09:37 ET | 15712 | 3.755 |
| 09:39 ET | 15519 | 3.715 |
| 09:42 ET | 14578 | 3.66 |
| 09:44 ET | 43777 | 3.715 |
| 09:46 ET | 14723 | 3.76 |
| 09:48 ET | 8322 | 3.76 |
| 09:50 ET | 7518 | 3.814 |
| 09:51 ET | 1151 | 3.77 |
| 09:53 ET | 20155 | 3.78 |
| 09:55 ET | 10730 | 3.77 |
| 09:57 ET | 21812 | 3.765 |
| 10:00 ET | 101597 | 3.7545 |
| 10:02 ET | 12633 | 3.725 |
| 10:04 ET | 7930 | 3.745 |
| 10:06 ET | 33141 | 3.74 |
| 10:08 ET | 1500 | 3.72 |
| 10:09 ET | 22579 | 3.7011 |
| 10:11 ET | 5257 | 3.7 |
| 10:13 ET | 1821 | 3.695 |
| 10:15 ET | 4370 | 3.665 |
| 10:18 ET | 15104 | 3.64 |
| 10:20 ET | 46595 | 3.65 |
| 10:22 ET | 10189 | 3.68 |
| 10:24 ET | 18960 | 3.7 |
| 10:26 ET | 14532 | 3.69 |
| 10:27 ET | 2400 | 3.69 |
| 10:29 ET | 15253 | 3.685 |
| 10:33 ET | 2934 | 3.685 |
| 10:36 ET | 300 | 3.68 |
| 10:38 ET | 13606 | 3.68 |
| 10:40 ET | 900 | 3.685 |
| 10:42 ET | 606 | 3.685 |
| 10:44 ET | 544 | 3.685 |
| 10:45 ET | 4332 | 3.695 |
| 10:47 ET | 9476 | 3.705 |
| 10:49 ET | 1658 | 3.72 |
| 10:51 ET | 2290 | 3.729806 |
| 10:54 ET | 100 | 3.725 |
| 10:56 ET | 1525 | 3.725 |
| 10:58 ET | 600 | 3.725 |
| 11:00 ET | 4311 | 3.725 |
| 11:02 ET | 1187 | 3.725 |
| 11:03 ET | 1118 | 3.725 |
| 11:07 ET | 6713 | 3.72 |
| 11:09 ET | 17077 | 3.715 |
| 11:12 ET | 53219 | 3.69 |
| 11:14 ET | 1333 | 3.685 |
| 11:16 ET | 135 | 3.685 |
| 11:18 ET | 16042 | 3.685 |
| 11:20 ET | 11008 | 3.675 |
| 11:21 ET | 34303 | 3.655 |
| 11:23 ET | 14925 | 3.665 |
| 11:25 ET | 12211 | 3.685 |
| 11:27 ET | 400 | 3.685 |
| 11:30 ET | 5449 | 3.685 |
| 11:32 ET | 13289 | 3.695 |
| 11:34 ET | 9107 | 3.705 |
| 11:36 ET | 4200 | 3.705 |
| 11:38 ET | 700 | 3.705 |
| 11:39 ET | 3600 | 3.705 |
| 11:41 ET | 5349 | 3.715 |
| 11:43 ET | 1900 | 3.73 |
| 11:45 ET | 2026 | 3.72 |
| 11:48 ET | 1363 | 3.73 |
| 11:50 ET | 435 | 3.725 |
| 11:52 ET | 2000 | 3.73 |
| 11:54 ET | 7546 | 3.7 |
| 11:56 ET | 2881 | 3.695 |
| 11:57 ET | 100 | 3.695 |
| 11:59 ET | 2269 | 3.6988 |
| 12:01 ET | 7049 | 3.685 |
| 12:03 ET | 8174 | 3.685 |
| 12:06 ET | 3321 | 3.675 |
| 12:08 ET | 12398 | 3.655 |
| 12:10 ET | 44471 | 3.678 |
| 12:12 ET | 5054 | 3.68 |
| 12:14 ET | 3885 | 3.68 |
| 12:15 ET | 2133 | 3.68 |
| 12:17 ET | 1000 | 3.6736 |
| 12:19 ET | 9921 | 3.655 |
| 12:21 ET | 25077 | 3.66 |
| 12:24 ET | 534 | 3.665 |
| 12:26 ET | 125960 | 3.64 |
| 12:28 ET | 3400 | 3.6499 |
| 12:30 ET | 47517 | 3.655 |
| 12:32 ET | 8725 | 3.66 |
| 12:33 ET | 400 | 3.665 |
| 12:35 ET | 2035 | 3.665 |
| 12:37 ET | 31114 | 3.64 |
| 12:39 ET | 23485 | 3.635 |
| 12:42 ET | 3379 | 3.63 |
| 12:44 ET | 2820 | 3.64 |
| 12:46 ET | 30151 | 3.63 |
| 12:48 ET | 12917 | 3.665 |
| 12:50 ET | 291 | 3.66 |
| 12:51 ET | 4329 | 3.65 |
| 12:53 ET | 5787 | 3.65 |
| 12:55 ET | 16828 | 3.64 |
| 12:57 ET | 9641 | 3.63 |
| 01:00 ET | 203015 | 3.62 |
Nov 12, 2024
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OB, RVNC, SMAR on Behalf of Shareholders, from 3:25PM ET on Tuesday Nov 12, 2024 by Dow Jones
3:25PM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 11, 2024
Nov 10, 2024
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC, from 11:00AM ET on Sunday Nov 10, 2024 by Dow Jones
11:00AM ET on Sunday Nov 10, 2024 by Dow Jones
Nov 9, 2024
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROIC, PWUP, RVNC on Behalf of Shareholders, from 10:30AM ET on Saturday Nov 09, 2024 by Dow Jones
10:30AM ET on Saturday Nov 09, 2024 by Dow Jones
Nov 8, 2024
Revance Stock - Investors of Revance Therapeutics Inc. Encouraged to Contact Kehoe Law Firm, P.C. - RVNC, from 3:36PM ET on Friday Nov 08, 2024 by Dow Jones
3:36PM ET on Friday Nov 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Revance Therapeutics Inc | 396.5M | -1.9x | --- |
Ginkgo Bioworks Holdings Inc | 450.0M | -0.7x | --- |
Voyager Therapeutics Inc | 309.7M | 11.7x | --- |
Akebia Therapeutics Inc | 449.5M | -9.3x | --- |
Vanda Pharmaceuticals Inc | 302.6M | -18.2x | -37.98% |
Coherus BioSciences Inc | 145.2M | -13.7x | --- |
Company Information
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.
Contact Information
- Headquarters
- 1222 Demonbreun Street, Suite 2000NASHVILLE, TN, United States 37203
- Phone
- 615-724-7755
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Angus Russell
- Chief Executive Officer, Director
- Mark Foley
- Chief Financial Officer
- Tobin Schilke
- Chief Medical Officer, Global Therapeutics Franchise Lead
- David Hollander
- Chief Commercial Officer
- Erica Jordan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $396.5M |
|---|---|
Revenue (TTM) | $247.0M |
Shares Outstanding | 104.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.84 |
EPS | $-1.91 |
Book Value | $-1.72 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | 1.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -67.83% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
